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Abstract
Plasmodium vivax is responsible for the majority of malaria cases outside Africa. Unlike
P. falciparum, the P. vivax life-cycle includes a dormant liver stage, the hypnozoite, which
can cause infection in the absence of mosquito transmission. An effective vaccine against
P. vivax blood stages would limit symptoms and pathology from such recurrent infections,
and therefore could play a critical role in the control of this species. Vaccine development in
P. vivax, however, lags considerably behind P. falciparum, which has many identified tar-
gets with several having transitioned to Phase II testing. By contrast only one P. vivax blood-
stage vaccine candidate based on the Duffy Binding Protein (PvDBP), has reached Phase
Ia, in large part because the lack of a continuous in vitro culture system for P. vivax limits
systematic screening of new candidates. We used the close phylogenetic relationship
between P. vivax and P. knowlesi, for which an in vitro culture system in human erythrocytes
exists, to test the scalability of systematic reverse vaccinology to identify and prioritise
P. vivax blood-stage targets. A panel of P. vivax proteins predicted to function in erythrocyte
invasion were expressed as full-length recombinant ectodomains in a mammalian expres-
sion system. Eight of these antigens were used to generate polyclonal antibodies, which
were screened for their ability to recognize orthologous proteins in P. knowlesi. These anti-
bodies were then tested for inhibition of growth and invasion of both wild type P. knowlesi
and chimeric P. knowlesi lines modified using CRISPR/Cas9 to exchange P. knowlesi
genes with their P. vivax orthologues. Candidates that induced antibodies that inhibited
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invasion to a similar level as PvDBP were identified, confirming the utility of P. knowlesi as a
model for P. vivax vaccine development and prioritizing antigens for further follow up.
Author summary
Malaria parasites cause disease after invading human red blood cells, implying that a vac-
cine that interrupts this process could play a significant role in malaria control. Multiple
Plasmodium parasite species can cause malaria in humans, and most malaria outside
Africa is caused by Plasmodium vivax. There is currently no effective vaccine against the
blood stage of any malaria parasite, and progress in P. vivax vaccine development has
been particularly hampered because this parasite species cannot be cultured for prolonged
periods of time in the lab. We explored whether a related species, P. knowlesi, which can
be propagated in human red blood cells in vitro, can be used to screen for potential P.
vivax vaccine targets. We raised antibodies against selected P. vivax proteins and tested
their ability to recognize and prevent P. knowlesi parasites from invading human red
blood cells, thereby identifying multiple novel vaccine candidates.
Introduction
Malaria remains a major global health challenge, with an estimated 228 million cases and
>400,000 deaths in 2018 [1]. While there are five Plasmodium species that can cause malaria
in humans, the majority of clinical cases are caused by P. falciparum and P. vivax. P. falciparum
causes almost all malaria cases in Africa, but P. vivax is the dominant cause of malaria in the
Americas, and causes a similar number of cases as P. falciparum in South-east Asia [1]. As well
as having different global distributions, the two species are also very different biologically,
which has significant implications for control. P. vivax, along with P. ovale, can form hypno-
zoites during its liver stage, which are quiescent forms of the parasite that remain dormant
from weeks to years in the liver, re-emerging upon stimulation to cause a relapse of malaria.
Hypnozoites can therefore act as a continuous source of infection even in the absence of active
transmission. This hurdle is made more significant by the fact that primaquine and tafeno-
quine, the only drugs used to treat hypnozoites, are frequently contraindicated due to their
toxicity in patients with glucose-6-phosphate deficiency, a common polymorphism in regions
of the world where P. vivax is most prevalent [2]. In addition, sexual stage development in P.
vivax is much more rapid than in P. falciparum [3], meaning that even with rapid treatment
with antimalarials, onwards transmission can still occur. These features limit the effectiveness
of current chemotherapeutic interventions, making the search for an effective vaccine even
more important for P. vivax.
The complex life-cycle of Plasmodium parasites present multiple potential intervention
strategies, including preventing transmission to the mosquito, targeting the liver stage to pre-
vent disease and relapse, and targeting blood stages to limit disease and also potentially lower
the potential of transmission from one infected individual to another. Vaccine targets across
all these stages of the parasite are under investigation, although in general far fewer antigens
have been studied in depth in P. vivax than in P. falciparum (reviewed in [4–6]). This is partic-
ularly the case for blood stage targets, where only a few targets such as P. vivax apical mem-
brane antigen 1 (PvAMA1) [7,8] and P. vivax merozoite surface protein 1 (PvMSP119) [9,10]
have advanced to pre-clinical study. The furthest advanced P. vivax vaccines, by far, are based
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on P. vivax Duffy Binding Protein (PvDBP), the only blood stage target that has reached clini-
cal Phase Ia trials [11–15]. This is in stark contrast to P. falciparum, where multiple targets in
different stages have been tested in Phase Ia (reviewed in [4]), and the RTS, S pre-erythrocytic
vaccine has advanced beyond Phase III to pilot testing across three countries in Africa [16].
More P. vivax targets clearly need to be screened if vaccine development for this species is to
advance.
It was previously believed that P. vivax was completely dependent on the interaction
between PvDBP and its receptor, Duffy Antigen Receptor for Chemokine (DARC) [17–20] to
invade human erythrocytes. However, it has recently been shown that P. vivax is also able to
infect individuals who are Duffy negative, so express little or no DARC on the surface of their
erythrocytes [21–23]. While the invasion of Duffy negative erythrocytes could still rely on
PvDBP [24,25], the sole focus on PvDBP as a vaccine candidate clearly needs to be reassessed
and additional targets evaluated, either as potential substitutes for PvDBP, or to be used in
combination with it. As noted above, erythrocyte invasion is a very complex process, and
while the process is much less well-understood in P. vivax than it is in P. falciparum [26], mul-
tiple other P. vivax ligands such as reticulocyte-binding protein 2 (RBP2b) [27], GPI-anchored
micronemal antigen (GAMA) [28], and erythrocyte binding protein 2 (ebp2) [29] have all
been shown or proposed to be involved in invasion, and could potentially be used alone or in
combination with PvDBP to target multiple steps of invasion, an approach that shows some
preliminary promise in P. falciparum [30].
In this study we took a reverse vaccinology approach to identify new P. vivax vaccine tar-
gets, building on previous work where we expressed a panel of 37 full-length recombinant P.
vivax vaccine targets predicted to be involved in erythrocyte invasion [31]. Polyclonal antibod-
ies were generated against 8 of these proteins, and the antibodies were tested for their ability to
inhibit merozoite invasion. P. vivax preferentially invades immature erythrocytes [32] making
even short-term culture of P. vivax exceedingly difficult [33–36], and limiting the development
of continuous culture of P. vivax in vitro, despite herculean efforts [37]. As a first-stage screen
we therefore performed invasion inhibition assays using P. knowlesi, a close phylogenetic rela-
tive of P. vivax [38,39] that has been adapted to in vitro culture in human erythrocytes [40,41]
and has been used previously as a model to assess P. vivax blood-stage vaccine candidates
[42,43]. P. knowlesi is highly amenable to genetic manipulation [40] and has been used in sev-
eral experimental genetic studies to investigate the role of specific genes in erythrocyte inva-
sion [44,45]. The adaptation of CRISPR-Cas9 genomic modification to P. knowlesi has
expanded the utility of this model further, by facilitating the direct swap of P. knowlesi genes
for their P. vivax counterparts [46], an approach that has already been used to aid the further
development of PvDBP as a vaccine candidate [47]. We combined screening against wild-type
and genome modified P. knowlesi parasites to prioritise new targets for P. vivax blood-stage
vaccine development, and in so doing present further evidence that P. knowlesi can be used as
a readily manipulatable in vitro model for P. vivax.
Results
Generation of polyclonal antibodies against new P. vivax vaccine
candidates
We have previously expressed a pilot library of 37 P. vivax proteins that were either shown to
localise to merozoite organelles with a role in invasion, or were predicted to do so based on the
localisation of their respective P. falciparum homologues [31]. In all cases, the full-length extra-
cellular domains of these proteins were expressed using a mammalian protein expression sys-
tem. This approach, which increases the likelihood of correct folding of disulphide-linked
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extracellular domains, has been used extensively for P. falciparum invasion-associated proteins
[48] to generate antigens capable of inducing potent invasion-inhibitory antibodies [30],
including for the major P. falciparum blood-stage vaccine target PfRh5 [49]. Comparing
immunoreactivity of native or heat-denatured epitopes and testing for protein-protein interac-
tions indicated that the previously produced P. vivax library was likely to consist of largely
functional proteins [31]. To test whether this library could also be used to generate inhibitory
antibodies, rabbit polyclonal antibodies were raised against eight targets, selected to represent
a range of predicted subcellular localizations and including PvDBP as a positive control
(Table 1). In all cases, antibodies were raised against the complete recombinant ectodomain of
the candidates. The immunisation schedule is outlined in the Methods, and total IgG was puri-
fied from serum using Protein A affinity chromatography to use in downstream assays.
Anti-Plasmodium vivax antibodies are able to recognise orthologues in P.
knowlesi
Given the difficulty in acquiring P. vivax ex vivo isolates for testing and technical issues with
even short-term culture, we used P. knowlesi as a model for screening new blood-stage vaccine
candidates, an approach that has previously been pioneered using both wildtype and geneti-
cally modified parasite lines [42,43,46,47]. P. knowlesi naturally infects the Kra cynomolgus
macaque (Macaca fascicularis) but causes severe zoonotic malaria in Southeast Asia [50], and
critically falls into the same clade of parasites as P. vivax [39]. While this phylogenetic relation-
ship is reflected in an overall higher degree of conservation between the P. vivax and P. know-
lesi genomes than the P. vivax and P. falciparum genomes [39], the degree of conservation
varies at the individual gene level. Sequence alignment between our P. vivax candidate proteins
and their orthologues in P. knowlesi showed a range of sequence similarities (Table 1), from a
pairwise identity score of 51% for PvDBP and its closest P. knowlesi orthologue PkDBPα, to
higher identity scores for several targets (P. vivax GPI-anchored micronemal protein;
PvGAMA, P. vivax 6-cysteine protein P12 (Pv12); P. vivax Asparagine-rich Protein (PvARP);
P. vivax Cysteine-rich Protective Antigen (PvCyRPA); P. vivax 6-cysteine protein P41 (Pv41)),
reaching 80% in the case of Pv41. In contrast the P. vivax Merozoite Surface Proteins 3.10
Table 1. Plasmodium vivax vaccine candidates.
P. vivax targets accession
number







PVX_113775 6-cysteine protein p12 PvP12 PKNH_1137300
(PkP12)
70%















PVX_090210 Asparagine-rich protein PvARP PKNH_0515300 (PkARP) 56%
PVX_09240 Cysteine-rich Protective Antigen PvCyRPA PKNH_0515800 (PkCyRPA) 68%
PVX_110810 Duffy Binding Protein PvDBP PKNH_0623500
(PkDBPalpha)
51%
PVX_000995 6-cysteine protein p41 PvP41 PKNH_0303000 (PkP41) 80%
https://doi.org/10.1371/journal.ppat.1008864.t001
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(PvMSP3.10) and P. vivax Merozoite Surface Proteins 7.1 (PvMSP7.1), both members of mul-
tigene families which are known to be highly polymorphic within and between Plasmodium
species, were chosen to represent proteins with a lower degree of conservation.
To explore whether variable degrees of homology would limit our ability to test specific tar-
gets in P. knowlesi, we first determined whether antibodies raised against P. vivax (Pv) targets
can recognise their P. knowlesi (Pk) orthologues in immunoblots using P. knowlesi schizont-
stage protein lysates (Fig 1). Antibodies raised against Pv12, PvARP, Pv41, PvMSP7.1 and
PvDBP produced a single immunoreactive band, while several bands were detected with anti-
bodies against PvGAMA, PvMSP3.10 and PvCyRPA, suggesting either post-translational mod-
ifications or proteolytic processing events, as is known to frequently occur in Plasmodium
merozoite proteins both in vitro and when expressed recombinantly in heterologous systems
[48]. While multiple factors could affect signal strength, including expression level in schizont
stages, there was some correlation between % Pv/Pk identity and the strength of the immuno-
blot signal, PvCyRPA being the exception with a weak detection signal despite 68% identity.
Antibodies against Pv12, PvGAMA, PvMSP3.10, PvCyRPA all detected proteins around their
expected molecular weight based on estimates from the corresponding orthologous protein in
P. knowlesi. In contrast, anti-PvARP, Pv41 and PvMSP7.1 detected proteins larger than the
expected molecular weight suggesting that they might migrate more slowly, which again is not
uncommon in extracellular Plasmodium proteins. Anti-PvDBP detected a protein half the
expected size suggesting either that PkDBPα (the closest P. knowlesi orthologue of PvDBP) is
highly processed, or that anti-PvDBP antibodies cross-react with multiple PkDBP proteins.
Fig 1. Anti-P. vivax polyclonal antibodies recognise proteins in P. knowlesi schizont protein lysates. Protein
extracts from enriched schizont-stage P. knowlesi cultures were separated on SDS-PAGE gels, transferred to
nitrocellulose and probed with anti-P. vivax polyclonal antibodies. Obtained size corresponding to the major bands
seen with each antibody is indicated, along with the expected size of the corresponding protein in P. knowlesi (upper
row) and its orthologue in P. vivax (middle row) in kiloDaltons (kDa). The arrows indicate the major bands for
PvMSP3.10, PVMSP7.1 and PvCyRPA. Note that the expected size of PkMSP7.1 of 39kDa is an average of the
molecular weight of four PkMSP7 like proteins (i.e. PKNH_1265900, PKNH_1266000, PKNH_1266100,
PKNH_1266300) that range from 32–46 kDa.
https://doi.org/10.1371/journal.ppat.1008864.g001
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Overall however, immunoblotting showed that the majority of anti-P. vivax antibodies recog-
nised P. knowlesi proteins.
Anti-P. vivax antibodies are able to localise orthologous target proteins to
P. knowlesi invasion organelles
To further explore the specificity of our anti-P. vivax antibody panel, we used them in indirect
immunofluorescence assays to test their ability to recognise mature P. knowlesi schizonts (Fig
2). Out of the 8 polyclonals, only anti-PvMSP3.10 (which shows the lowest percentage of iden-
tity between Pv and Pk) did not produce a specifically localised signal (Fig 2). Anti-PvGAMA,
PvCyRPA, PvDBP and PvARP all labelled punctate foci within the merozoites, while anti-
Pv12, Pv41 and PvMSP7.1 all appeared to label the entire merozoite surface. No staining was
observed with pre-immune antiserum (S1 Fig), confirming that the labelling was antigen-
specific.
To establish the specific location of each antigen, anti-P. vivax antibodies were used in co-
localization experiments with antibodies specific to proteins of known cellular locations:
AMA1, MSP1-19 and GAP45 which are located in microneme, merozoite surface and inner
membrane complex (IMC), respectively (see Methods for antibody sources). Anti-Pv12, Pv41
and PvMSP7.1 all showed a clear co-localization with anti-MSP1 (Figs 3A and S2A) suggesting
that their orthologous targets are located on the merozoite surface. Anti-PvGAMA and, to a
lesser extent, anti-PvCyRPA and anti-PvDBP, co-localised with anti-AMA1, suggesting that
their orthologous targets are located in apical secretory organelles such as the micronemes
(Figs 3B and S3). Anti-ARP appeared to be apically located but did not co-localise with any
markers that we tested (Figs 3B and S3), such that its exact location remains to be determined.
To confirm that antibodies against Pv12, Pv41 and PvMSP7.1 were labelling the merozoite sur-
face and not the IMC, markers of which produce similar staining patterns in late schizonts, co-
staining with the IMC marker anti-GAP45 was also carried out in late trophozoites/early schiz-
onts, as the IMC and merozoite surface are easier to distinguish earlier in the cell cycle. In all
cases there was no co-localisation with anti-GAP45 in these earlier stages (S2B Fig), confirm-
ing a merozoite surface, not an IMC, location.
Screening anti-P.vivax antibodies for inhibitory activity in P. knowlesi
identifies novel invasion-blocking candidates
Having established that anti-P. vivax antibodies could be used to specifically detect homo-
logues in P. knowlesi, we explored whether the same antibodies could inhibit P. knowlesi eryth-
rocyte invasion. Serial two-fold dilutions of purified total IgG were prepared starting from 10
mg/ml, and incubated with synchronized ring-stage P. knowlesi parasites for 24 hours in the
presence of CellTrace Far Red uninfected erythrocytes. Dual colour flow cytometry was used
to measure invasion, which was quantified as the percentage of erythrocytes that were both
SYBR green and CellTrace Far Red positive after 24 hours, compared to assays performed in
the absence of any antibodies or in the presence of pre-immune IgG (see S4 Fig). All antibody
combinations were carried out in two biological replicates, each consisting of three technical
replicates. As shown in Fig 4, compared to the positive and negative controls for inhibition
(heparin and rabbit IgG respectively), antibody activity fell into two broad groups: inhibitory
(Fig 4B–4E, anti-Pv12, Pv41, PvGAMA and PvDBP which gave IC50 values of 4.5, 5.6, 6.1 and
4.2 mg/ml respectively) and not inhibitory (Fig 4F–4J, anti-PvARP, PvCyRPA, PvMSP7.1,
PvMSP3.10). The low level of inhibition observed with anti-PvMSP7.1 and PvMSP3.10 could
be due to the low degree of homology between Pv and Pk homologs, and the lack of inhibition
observed with the anti-PvMSP3.10 was consistent with the absence of cross-reactivity with
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PkMSP3 homologues in immunofluorescence assays. Strong inhibition with anti-PvDBP, the
only P. vivax blood stage vaccine target in the advanced stage of vaccine development, was
confirmatory and comparable to other studies [46]. Antibodies to two other targets, Pv12 and
Fig 2. Immunolocalisation of P. knowlesi proteins using polyclonal anti-P. vivax antibodies. Antibodies raised
against P. vivax vaccine candidates were used in immunofluorescence assays using enriched schizont-stage P. knowlesi
parasites. Rabbit polyclonals were detected using Alexa 555-labeled anti-rabbit secondary antibody, and compared
with parasite nuclei as detected with Hoechst 33342. Merge is an overlay of Alexa 555 and Hoeschst. Scale bar is 2
micrometers.
https://doi.org/10.1371/journal.ppat.1008864.g002
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PvGAMA, had similar IC50s to anti-PvDBP, while antibodies to Pv41, which interacts with
Pv12 [31], also had strong inhibition. The levels of total IgG that was required to inhibit inva-
sion was broadly similar to that observed in other studies of P. falciparum vaccine targets [30],
including the major target PfRH5 [49,51] when total IgG is being used in such assays. Purify-
ing antigen-specific antibodies from polyclonal serum would likely have reduced the concen-
tration required for inhibition just as it does for PfRH5 in both human and non-human
Fig 3. Colocalisation of P. knowlesi homologs of P. vivax vaccine candidates with antibodies to proteins of known
cellular location. P. knowlesi proteins were localised using rabbit polyclonal antibodies raised against P. vivax vaccine
candidates and co-stained with rat antibodies against A) anti-PkMSP1 or B) anti-PfAMA1 for colocalization (origin of
antibodies is described in Methods). Alexa Fluor 555 goat-anti rabbit and Alexa Fluor 488 goat-anti rat were used as
secondary antibodies, and parasite DNA localised using Hoechst 33342. The first Merge column is an overlay of Alexa
555 and Alexa488 staining, while the second Merge column is an overlay of Alexa 555, Alexa488 and Hoeschst. Scale
bar is 2 micrometers.
https://doi.org/10.1371/journal.ppat.1008864.g003
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primate vaccination studies [52,53], but was not possible in this study because of the number
of antibodies and assays being carried out.
Gene editing in P. knowlesi establishes that Pk41 and PkGAMA are not
essential for blood-stage growth
Gene essentiality is one potential prioritisation factor in ranking vaccine candidates, as target-
ing the product of a gene that is absolutely required for parasite development is by definition
more likely to yield growth inhibitory activity. Given that antibodies against Pv12, Pv41, and
PvGAMA all inhibited P. knowlesi growth, we used genome editing to determine whether the
orthologous genes in P. knowlesi could be knocked out. We also targeted PkARP as a positive
control, as anti-PvARP antibodies had no inhibitory effects on P. knowlesi (Fig 4), while con-
structs targeting PkDBPα were included as a negative control, as this gene has previously been
shown to be essential for invasion of human erythrocytes [46,54]. Gene targeting was carried
out using a CRISPR-Cas9 two-vector approach, with one vector containing Cas9 and guide
RNA expression cassettes as well as the selection marker, while the other one was a donor tem-
plate for repair consisting of eGFP flanked by 5’ and 3’ untranslated regions of each respective
gene; three different gRNA constructs were generated and used for every gene and successful
knockout resulted in the replacement of the endogenous gene with a GFP expression cassette
(S5A Fig). Transfection of P. knowlesi was followed by selection with 100 nM pyrimethamine
for 6 days to select for Cas9 expression, and cultures were maintained for up to 3 weeks. Trans-
fections were repeated at least twice for each pair of constructs.
Parasites were recovered from all transfections. Genomic DNA was extracted from recov-
ered lines, and used for genotyping to establish whether integration had occurred. Only
Fig 4. Dose-dependent inhibition of wild-type P. knowlesi by polyclonal antibodies to P. vivax vaccine candidates. P.
knowlesi parasites were grown in the presence of a dilution series of anti-P. vivax antibodies, with invasion events into
fluorescently labelled red blood cells quantified using dual colour flow cytomtery (method summarised in S4 Fig). The effect
of antibodies was calculated as a percentage, comparing invasion in the presence of antibodies to invasion in the absence of
antibodies. Heparin and total IgG from unimmunised rabbits were used as positive and negative controls respectively. The
data presented includes observations from two independent experiments, each of which had three replicate wells for each
condition/antibody concentration. To determine if the inhibition was statistically significant, all treatments were
independently compared to the effect of the same concentration of non-immune rabbit IgG using Mann-Whitney-Wilcoxon
test: �p = 0.05–0.01; ��p<0.01.
https://doi.org/10.1371/journal.ppat.1008864.g004
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parasites transfected with Pk41 and PkGAMA knockout constructs gave bands of the size
expected if gene deletion had occurred (S5B Fig). Whole genome sequencing analysis con-
firmed this result, showing no reads mapping to the deleted regions of the wildtype (WT) P.
knowlesi genome (S6 and S7 Figs), indicating that integration of the knock-out construct had
occurred. By contrast, genotyping of parasites transfected with Pk12, PkARP and PkDBPα con-
structs did not differ from WT cultures. No WT band was amplified for Pk41 and PkGAMA
knockout lines, whereas WT parasite controls yielded bands of the expected size (S5B Fig).
Pk41 and PkGAMA therefore appear to be non-essential for P. knowlesi growth, whereas Pk12,
PkARP and PkDBPα were not able to be disrupted using this approach.
To confirm that Pk41 and PkGAMA expression was absent in the knockout lines, fluores-
cence and immunofluorescence assays were performed. Both knockout lines expressed eGFP
(Fig 5A and 5B), while localisation assays with anti-Pv41 and anti-PvGAMA gave no specific sig-
nal (Fig 5C), showing only background staining in clear contrast to WT parasites (Figs 3 and 4).
This confirms that these parasites were not expressing Pk41 and PkGAMA, and therefore that
Pk41 and PkGAMA are redundant for intra-erythrocytic growth, despite the fact that anti-P41
and anti-GAMA antibodies were shown to inhibit parasite growth (Fig 4). Growing the knock-
out strains over nineteen cycles showed both knockout strains grew slightly, but significantly,
slower than wild-type strains (S8 Fig; Gamako vs WT; p41ko vs WT), suggesting that while these
genes play some role in in vitro growth, even if they are not absolutely required for it.
Allele replacement of P. knowlesi genes with P. vivax orthologues increases
the inhibitory effect of anti-P. vivax antibodies
A true test of the inhibitory effectiveness of the anti-P. vivax antibodies would be in the context
of the proteins that they were raised against, but P. vivax culture and invasion assays are not
available for routine use. To test an alternative approach, we sought to replace P. knowlesi tar-
get genes with their P. vivax orthologues, generating chimeric P. knowlesi strains expressing
P. vivax proteins. Replacement constructs were created in which the Pv12, Pv41, PvGAMA and
PvARP open reading frames were created by gene synthesis to be recodonised and flanked by
the 5’ and 3’ UTRs of their P. knowlesi counterparts, and these were transfected in combination
with the same Cas9/gRNA vectors used in the knockout studies, in order to replace Pk12,
Pk41, PkGAMA and PvARP with Pv12, Pv41, PvGAMA and PvARP respectively (S9A Fig).
After selection of transfected parasites with 100 nM pyrimethamine and expansion of the
resulting parasites lines, genomic DNA was extracted for genotyping. All lines gave bands of
the expected size (S9B Fig) indicating that integration of these replacement constructs had
occurred at the expected locus, and no WT bands were detected. Whole genome sequencing
analysis confirmed replacement as no reads mapped at the targeted region (S10–S13 Figs)
because the Pv gene sequence had been codon-optimised to the human genome to minimise
the chance of recombination within the coding sequence, and restrict crossover to the flanking
regions, thereby enabling complete gene replacement.
Localisation assays with anti-Pv12, anti-PvARP, anti-Pv41 and anti-PvGAMA antibodies all
gave specific signals in the replacement lines (Fig 6) with anti-Pv12 and Pv41 (Fig 6A and 6C) indi-
cating merozoite surface localisation, while anti-PvGAMA and PvARP (Fig 6B and 6D) appeared
as punctate signals, matching the signals in wildtype P. knowlesi parasites (Figs 2 and 3). These chi-
meric parasites are therefore viable and able to correctly express and localize Pv12, PvARP, Pv41
and PvGAMA. The chimeric P. knowlesi strains had similar growth rates as the WT strains, and in
the case of Pv41 and PvGAMA, also grew faster than the relevant Pk knockout strains (S8 Fig),
indicating that the P. vivax genes can substitute for the function of their P. knowlesi counterparts,
and emphasizing the phylogenetic relationship between the two parasites.
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Fig 5. Gene editing can delete PkP41 and PkGAMA in P. knowlesi. Pkp41 and PkGAMA were replaced with eGFP
to generate Pk41KO and PkGAMAKO strains respectively, as described in the Methods. A) Flow cytometry to
establish eGFP expression in knockout lines. Enriched knock out and wild-type P. knowlesi cultures at late stages were
labelled with SYBR green in 1X PBS and incubated for one hour after which they were quantified by flow cytometry.
Events were gated as both SYBR green and GFP negative (lower left—uninfected RBCs), SYBR green only positive
(lower right—RBCs infected with parasites not expressing GFP) and both SYBR green and GFP positive (upper right—
RBCs infected with parasites not expressing GFP). Both KO lines expressed GFP, confirming integration of the KO
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To test whether replacing the P. knowlesi genes with their P. vivax counterparts increased
the inhibitory activity of anti-P. vivax antibodies, we tested for invasion inhibition comparing
WT and chimeric replacement lines. In all cases inhibition the chimeric allele-replaced lines
were inhibited more effectively with the anti-P. vivax antisera, resulting in lower IC50 values
(Figs 7 and S14). This suggests that while P. knowlesi is a useful model as a first screen for P.
vivax reverse vaccinology studies, sequence differences between P. vivax antigens and their P.
knowlesi orthologues can lead to underestimation of the inhibitory effect of anti-P. vivax anti-
bodies when only wildtype P. knowlesi parasites are used. However, the IC50 values for wild-
type P. knowlesi was lower in these assays than those we had performed previously (Fig 4),
raising concern that repeated freeze-thaws had diminished the inhibitory activity of the anti-
bodies. While this technical explanation does not affect comparability between activity on
wildtype and allele swap lines within Fig 7 as they were performed at the same time and with
the same antibody samples, to address any concerns about reproducibility, we generated new
rabbit polyclonal antibodies for Pv12, Pv41, PvGAMA and PvDBP. The IC50 values (3.9, 3.0,
3.2 and 4.4 mg/ml respectively, S15B Fig) from these new antibodies were broadly similar to
those generated in Fig 4 (4.5, 5.6, 6.1 and 4.2 mg/ml respectively), confirming that while the
absolute values may differ between experiments and different antibody batches, these targets
reproducibly induce antibodies with similar GIA IC50s to PvDBP. We also generated Fabs
from these new antibodies and confirmed that they too had GIA activity (S15A Fig), which in
the case of anti-Pv12 and Pv41 was similar to inhibition by total IgG, reducing concern about
possible bivalent effects of IgG.
Discussion
To date only a limited number of Plasmodium vivax blood stage vaccine candidates have been
investigated [5,6]. This is in large part because it is currently not possible to continuously cul-
ture P. vivax blood stages in vitro, which rules out many biological assays. P. knowlesi has a
close phylogenetic relationship with P. vivax and has been adapted to in vitro culture in
human erythrocytes [40,41]. As a result, P. knowlesi has been recently tested as an in vitro
model to screen for P. vivax vaccine candidates, both by screening wild-type human-adapted
P. knowlesi with antibodies raised against recombinant P. vivax proteins [42,43] and in the
case of PvDBP, using CRISPR-Cas9 genome engineering to replace the PkDBPα locus with
PvDBP to facilitate detailed dissection of this major vaccine candidate [46,47]. In this study we
combined these approaches, both screening antibodies raised to P. vivax antigens against wild-
type P. knowlesi parasites, and using systematic genome modification to both delete and swap
P. knowlesi genes for their P. vivax orthologues, in order screen for new blood-stage P. vivax
antigens using a panel of polyclonal antibodies generated against candidates from a previously
published library of P. vivax schizont expressed proteins [31]. We focused on seven P. vivax
targets: two merozoite surface proteins (PvMSP7.1 and PvMSP3.10); two 6-Cysteine domain
proteins (Pv12 and Pv41) and three proteins not belonging to other families (PvGAMA,
PvCyRPA and PvARP), with PvDBP included as a positive control.
cassette. B) eGFP expression in knock-out P. knowlesi strains as compared to wild-type P. knowlesi, imaged using
fluorescence microscopy. Parasite nuclei were stained using Hoechst 33342; Merge is an overlay of eGFP and
Hoeschst, confirming parasite expression of GFP. Scale bar is 2 micrometers. C) Proteins in knock out and wild-type
P. knowlesi strains were localised using P. vivax polyclonal antibodies and Alexa Fluor 555 labeled secondary antibody
then imaged using fluorescence microscopy. Localisation in both knock out and wild-type Pv41 and PvGAMA was
performed using anti-Pv41 and anti-PvGAMA antibodies respectively; in both cases the KO line produced only diffuse
background staining, confirming knockout of the P. knowlesi genes. Parasite nuclei were stained with Hoechst 33342;
Merge is an overlay of Alexa 555 and Hoeschst. Scale bar is 2 micrometers.
https://doi.org/10.1371/journal.ppat.1008864.g005
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There was a broad correlation between the ability of anti-P. vivax antibodies to specifically
recognise their P. knowlesi orthologues in immunoblot and immunofluorescence assays and
the percent identity within the P. vivax/P. knowlesi antigen pairs. However, it is worth noting
that a single dominant protein band was identified in 5/8 cases, and clear intracellular
Fig 6. Gene editing to replace P. knowlesi target genes with orthologous P. vivax candidate genes. Pvp12, PvARP,
Ppv41 and PvGAMA gene sequences were used to replace Pkp12, PkARP, Pkp41 and PkGAMA in wild-type P.
knowlesi to create lines Pk12Rep, PkARPRep, Pk41Rep and PkGAMARep allele replacement lines. Proteins in allele-
replacement and wild-type P. knowlesi strains were localised using anti-P. vivax polyclonal antibodies and Alexa Fluor
555 labelled secondary antibody, and imaged using fluorescence microscopy. Parasite nuclei were stained with Hoechst
33342; Merge is an overlay of Alexa 555 and Hoeschst. In all cases localisation was the same in the wild-type and allele-
replacement lines. Scale bar is 2 micrometers.
https://doi.org/10.1371/journal.ppat.1008864.g006
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localisations defined in 7/8 cases, despite levels of identity as low as 50%, suggesting the system
has broader utility than primary amino acid homology levels alone might indicate. This high
level of cross-reactivity may be in part be due to our strategy of raising polyclonal antibodies
against full-length protein ectodomains, whereas many antigen studies focus only on smaller
sub-domains, which limits the chances that cross-reactive responses will be generated. There is
also some evidence that the eukaryotic expression system we use increases the likelihood of
generating antibodies against folded, functional domains [48], which are more likely to be of
utility in assays such as immunofluorescence or growth inhibition, where conformation-
dependent epitopes are more important. Using these antibodies in growth inhibition assays
revealed robust dose-dependent inhibition of P. knowlesi growth by anti-Pv12, Pv41 and
PvGAMA antibodies, in some cases on a similar level to anti-PvDBP antibodies. As with all
studies using polyclonal antibodies, some caution about the potential for cross-reactivity with
other targets is required, although we do not believe this is a major issue here as in all cases
immunofluorescence staining was primarily at expected locations, suggesting either cross-
reaction was minimal or occurring only with proteins located in the same organelles as the pri-
mary target, which seems unlikely. In the case of two antibodies, anti-Pv41 and anti-PvGAMA,
deletion of their respective P. knowlesi orthologues eliminated all antibody staining, establish-
ing that if cross-reaction was occurring it was below the detection limits of our microscopy
assays. Nonetheless, if any of these targets is pursued further, more definitively target-specific
reagents such as monoclonal antibodies or affinity-purified antigen-specific antibodies are
clearly required.
Fig 7. Inhibition by polyclonal antibodies to P. vivax vaccine candidates is increased in chimeric P. knowlesi
strains expressing homologous P. vivax proteins. Invasion inhibition assays were carried out as detailed in the
Materials and Methods sections and summarised in S4 Fig. Chimeric P. knowlesi strains expressing Pvp12 (PkPv12),
PvARP (PkPvARP), Pvp41 (PkPv41) and PvGAMA (PkPvGAMA) were incubated with anti-PvP12, anti-PvARP, anti-
PvP41 and anti-PvGAMA antibodies respectively and compared to inhibition in wildtype P. knowlesi. This data
represents observations from two independent experiments each with three replicate wells per each treatment. To
determine if the inhibition was statistically significant, all treatments were independently compared to the same
concentration of total IgG from non-immunised rabbits using Mann-Whitney-Wilcoxon test with a p-value threshold
of 0.05; the inhibition of wild-type and chimeric parasites was also compared using the same approach. Black asterisks
represents p-values obtained from comparison with non-immune rabbit IgG while red asterisks represents p-values
obtained from comparison of wild-type and mutant parasites. �p = 0.05–0.01; ��p<0.01.
https://doi.org/10.1371/journal.ppat.1008864.g007
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Pv12 and Pv41 are members of a family of 6-cysteine domain proteins, other members of
which are under investigation as transmission-blocking vaccine targets in P. falciparum [55–
57]. The P. falciparum orthologues of Pv12 and Pv41 form a heterodimer and are localised on
the merozoite surface [58]. We have previously shown that Pv12 and Pv41 are also able to het-
erodimerize [31], and here we show that their P. knowlesi orthologues also colocalise to the
merozoite surface, suggesting key elements of the function of these two proteins are conserved
across Plasmodium species. However, there are also elements that are different. Immunoepide-
miology studies show that antibody responses to Pv12 and Pv41 are commonly induced by
exposure to P. vivax infection and have been associated with protection against severe P. vivax
malaria, in keeping with the inhibitory activity of anti-Pv12 and Pv41 antibodies shown here
[31,59–61]. By contrast, in P. falciparum, anti-Pf12 and Pf41 antibodies have no inhibitory
effects on parasite growth in vitro, and the genes can be deleted, suggesting a level of functional
redundancy in this species [58]. Previous immunofluorescence studies of Pv12 in P. vivax sug-
gest that unlike its P. falciparum homologue Pf12 and our experiments with P. knowlesi it
localises to the rhoptries rather than merozoite surface [62], although whether this apparent
difference is due to differences in the stage of the parasite during erythrocytic schizogony used
in the assays is not known.
We localised PkARP to the apical region of the merozoite, suggesting a possible location in
the rhoptries like the PfARP homologue in P. falciparum [63], but in contrast to previous stud-
ies suggesting a merozoite surface location in P. vivax and P. knowlesi [64,65]; again, experi-
mental differences in the stage of parasites used might explain the different observations.
PkGAMA also localised to apical organelles, replicating previous observations of a micronemal
location in P. vivax [28] and P. falciparum [66,67]. We were unable to inhibit P. knowlesi
growth using anti-PvARP antibodies, contradicting what has been shown in P. knowlesi [65]
and P. falciparum [63]. However, when we replaced PkARP with PvARP, there was a reversal
of the activity of anti-PvARP, suggesting that PkARP may lack key inhibitory epitopes recog-
nised by our polyclonals, which were raised against PvARP. Anti-PvGAMA had invasion and
growth inhibitory effects on P. knowlesi in both WT and chimeric lines, replicating the obser-
vations of anti-PfGAMA effects on P. falciparum [66], suggesting a conserved role of this pro-
tein in invasion across species. Immunoepidemiology studies also show that antibody
responses to PvARP and PvGAMA are commonly induced by exposure to P. vivax infection
and in some cases have been associated with protection against severe P. vivax malaria [31,59–
61,68].
How do these relatively new candidates compare to the much more well-studied vaccine
candidate PvDBP? Clearly PvDBP has been the subject of decades of work, meaning that there
are multiple lines of evidence supporting its candidacy. One well-established concern about
PvDBP is that some regions of the protein are polymorphic and can induce strain-specific anti-
body responses [69,70], although extensive work has shown that the issue of polymorphism
may be able to be overcome with epitope engineering [14,71,72]. In addition, Phase I trials
show that it is possible for a PvDBP immunogen to elicit cross-reactive antibodies that inhibit
multiple diverse PvDBP alleles and strains [12,15,47], and cross-reactive human antibodies to
PvDBP can be isolated from individuals previously exposed to P. vivax [73]. PvDBP clearly
therefore remains a high priority vaccine candidate, but past experience with Plasmodium vac-
cines suggests that relying only on a single candidate leaves vaccines vulnerable to immune
escape, meaning a systematic and comprehensive approach to identify additional candidates is
essential, such as the one we pilot here.
One question in weighing up the candidacy of any new vaccine antigen is whether the gene
that encodes it is essential for parasite growth, as targeting a non-essential gene would seem
likely to select for parasites that do not rely on the gene product, and so are able to escape the
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vaccine. According to the current model, PvDBP is essential for invasion, as P. vivax primarily
invades via the interaction between PvDBP and its host receptor, Duffy Antigen Receptor for
Chemokine (DARC) [17–20]. While it has now clearly been demonstrated that P. vivax is also
able to infect individuals who are Duffy negative, lacking DARC expression on their red blood
cell surface [21–23], this could either be because P. vivax is able to utilize other ligands for
invasion such as PvRBP2b [27] and erythrocyte binding protein 2 (ebp2) [29], or that PvDBP
is still involved in the invasion of Duffy negative cells [24,25]. It is also worth noting that the
genetic essentiality of PvDBP for parasite growth has never been able to be directly tested, as P.
vivax cannot be cultured and therefore cannot be genetically manipulated. Studies in P. know-
lesi, which has three homologues of PvDBP, suggest that at least one is required for invasion of
human erythrocytes [46,54], but whether this is true of PvDBP remains to be proven
unequivocally.
In the case of the four candidates identified by initial screening with wildtype P. knowlesi,
there are clear 1:1 orthologues between P. vivax and P. knowlesi, providing an strong rationale
to use P. knowlesi genetic tools to explore candidates. We utilised the fact that P. knowlesi can
be readily genetically manipulated [40,44–46] to explore whether Pv12, Pv41, PvGAMA and
PvARP were essential for parasite growth. Pk41 and PkGAMA could be experimentally deleted,
while Pk12 and PkARP could not, even though both anti-PvP41 and PvP12 antibodies had
invasion and growth inhibitory effects on WT P. knowlesi. The fact that Pk12 and PkARP
could not be deleted using this strategy does not of course confirm that these genes are essen-
tial for blood stage growth, as different constructs or a different strategy could have had a dif-
ferent outcome. However, three different gRNA constructs were used for these as for every
gene, which does decrease the likelihood that ineffective Cas9 cleavage alone is an explanation
for the fact that Pk12 and PkARP could not be readily deleted.
The fact that Pk41 and PkGAMA could be deleted, whereas antibodies that recognise them
inhibit growth, at first glance seems contradictory, even though there was a small but statisti-
cally significant growth defect in both knockout lines suggsteing some role for these genes dur-
ing routine blood-stage growth. The difference between the antibody and knockout data could
be explained if the antibodies raised against Pv41 and PvGAMA recognized multiple targets in
P. knowlesi, but these antibodies generated only non-specific immunofluorescence staining
with the knockout strains, suggesting that the antibodies are specific. An alternative explana-
tion is that the process of genetic deletion, which takes some weeks to recover modified para-
sites, provides an opportunity for the parasites to adapt to the loss of a specific gene, for
example by up-regulating the expression of other genes. By contrast, growth inhibition assays
using antibodies occur in a single cycle, which the parasites may find it harder to adapt to.
There is certainly precedence for differences between antibody inhibition and genetic deletion
data from the study of invasion-associated proteins in P. falciparum. Antibodies raised against
PfEBA175, for example, are able to inhibit invasion in multiple P. falciparum strains [74,75],
yet the PfEBA175 gene can be deleted without affecting parasite growth [76] and in some cases
gene deletion has been shown to be accompanied by a transcriptional switch in gene expres-
sion which presumably helps the parasites to survive in the absence of PfEBA175, indicative of
the kind of adaptation approach that can happen during genetic manipulation experiments
[77]. Similarly anti-Pf12 and anti-Pf41 antibodies were able to inhibit P. falciparum growth,
albeit at low levels (15–20%), yet both genes could be disrupted [58]. Genetic deletions and
inhibitory antibodies are different model approaches to understand protein function, each
with strengths and weaknesses. Overall though, the lack of genetic essentiality for Pv41 and
PvGAMA does make it reasonable to argue that Pv12 and PvARP should have a higher priority
for follow-up.
PLOS PATHOGENS Screening for novel Plasmodium vivax blood-stage vaccine targets
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008864 July 1, 2021 16 / 32
This study clearly highlights several advantages of the P. knowlesi system as a model for test-
ing P. vivax blood-stage antigens, some of which have also been emphasised in previous drug
[78] and vaccine [42,43,46,47,65] studies. A key one is accessibility—access to ex vivo P. vivax
samples is limited and samples are precious, whereas we were readily able to perform multiple
in vitro assays using a human-erythrocyte adapted line of P. knowlesi [40]. A second is the
genetic tractability of the system, where transfections, gene deletions and allele replacements,
while not precisely routine, are certainly readily achievable [44–46,78]. There are however
always limitations in using one species as a model for another, and this study reveals some of
these. The study relies on antibodies that were generated against P. vivax proteins being able to
cross-react with their P. knowlesi orthologues, and while in almost all cases this proved possi-
ble, there was some correlation between the strength of cross-reactivity and the % identity
between antigen pairs, meaning the P. knowlesi model will almost certainly be more useful for
some antigens than others. The genetic tractability of P. knowlesi offers a potential solution to
this problem, as we have shown, by allowing the replacement of endogenous P. knowlesi genes
with their P. vivax orthologues, implying that antibodies can be tested against the precise
sequence they were generated against. This approach relies on the ability of a P. vivax gene to
substitute for P. knowlesi gene function, which may not always be the case, but in all four
instances tested here, as well as the Pv/PkDBP swaps carried out previously (where the Pv/
PkDBP swap behaved very similarly to ex vivo P. vivax assays, and much better than assays
using recombinant proteins) [46,47], this has not proven a problem, despite in the case of
PvDBP/PkDBPα, relatively low levels of overall homology. Ultimately however, no model sys-
tem is perfect, even ex vivo culture of P. vivax itself, which after all is only a model for in vivo
growth. It would be extremely useful to the P. vivax vaccine field to carry out a head-to-head
comparison across all the four currently available functional models—wildtype P. knowlesi,
genetically modified P. knowlesi with allele modifications to insert P. vivax genes, P. cynomo-
logi and P. vivax ex vivo assays. The targets identified here, Pv12, Pv41, PvARP and PvGAMA,
along with PvDBP, present a perfect opportunity to carry out such a test. It is also worth noting
that genetically modified lines such as those generated here could also prove very useful for
immunoepidemiological work, such as using them to test the inhibitory activity of antibodies
purified from P. vivax exposed patient sera.
To conclude, using both antibody and genetic approaches, we exploited the phylogenetic
relationship between P. knowlesi and P. vivax to explore blood-stage P. vivax vaccine targets.
The data suggests a hierarchy of possible targets, with Pv12 and PvARP being the highest pri-
ority as they appear to be genetically essential and can be targeted with inhibitory antibodies,
Pv41 and PvGAMA in a second tier as they can be inhibited with antibodies but also geneti-
cally deleted, while PvMSP7.1, PvMSP3.10 and PvCyRPA would seem to have the lowest prior-
ity, at least on the basis of the assays we performed. There are of course caveats to this kind of
ranking, as with any ranking. Firstly, we did not pursue PvMSP7.1, PvMSP3.10 and PvCyRPA
in detail after antibodies against them did not yield inhibitory activity in initial experiments,
which could potentially be due to low levels of homology between P. vivax and P. knowlesi in
these proteins. In the case of PvCyRPA, encouraging data from P. falciparum [79] and the find-
ing that PkCyRPA is essential for P. knowlesi invasion [45] both suggest that further investiga-
tion of this target is justified. Secondly, comparing antibody inhibition on the basis of total
IgG IC50 has its limits—generating antigen-specific antibodies for each target would be a
much more accurate basis on which to carry out comparisons, but was not possible in this
study due to the sheer number of different assays and approaches being employed. Detailed
follow-up should inevitably involve the generation of monoclonal antibodies for more datailed
mechanism of action studies.
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The overall approach reinforces other studies [42,43,46] to suggest that P. knowlesi can
serve as an accessible and efficient model to test P. vivax vaccine candidates. While this offers a
promising route to scale-up P. vivax blood-stage vaccine candidate screening, as noted above
there are advantages and limitations to any model system. Until a robust P. vivax culture sys-
tem is established, which despite extensive effort by multiple groups [33–37] does not seem
likely soon, it will be advisable to use multiple models to screen for candidates, and be clear
and upfront about the limitations inherent in all of them.
Materials and methods
Ethics statement
Human O+ erythrocytes were purchased from NHS Blood and Transplant, Cambridge, UK,
and all samples were anonymised. The work complied with all relevant ethical regulations for
work with human participants. The use of erythrocytes from human donors for P. falciparum
culture and binding studies was approved by the NHS Cambridgeshire 4 Research Ethics
Committee (REC reference 15/EE/0253) and the Wellcome Sanger Institute Human Materials
and Data Management Committee.
In vitro parasite culture
Plasmodium knowlesi parasites were maintained as described in [40]. Briefly, P. knowlesi strain
A1-H.1 was propagated in human O+ erythrocytes (UK NHS Blood and Transplant), in RPMI
1640 supplemented with Albumax (Thermo Fisher Scientific), L-Glutamine (Thermo Fisher
Scientific), Horse serum (Thermo Fisher Scientific), Gentamicin (Thermo Fisher Scientific).
The cultures were kept at 2% hematocrit, gassed using a mixture of 5% CO2, 5% O2 and 90%
Nitrogen, while being monitored three times per week by counting parasitemia using light
microscopy with media change or splitting as appropriate.
Synchronization and enrichment of Plasmodium knowlesi
Synchronization was performed by enriching late stage parasites using Histodenz (Sigma
Aldrich) as described in [40]. Briefly, parasites were resuspended in 5ml complete media and
layered on top of 5 ml of 55% Histodenz in complete culture media in a 15 ml tube (Greiner).
The mixture was then centrifuged for 3 minutes at room temperature, 1500 g, acceleration 3
and brake 1, resulting in late stage parasites becoming enriched at the interface. For inhibition
assays, these parasites were returned to culture, and assays set up after reinvasion had occurred
in the subsequent cycle. For protein extracts, immunofluorescence assays and transfections,
this was repeated over three consecutive cell cycles to create very tightly synchronized para-
sites, with schizont samples from a fourth cycle of Histodenz purification used for subsequent
analysis.
Antibody production and purification
Rabbits were immunized with 1mg of his-tagged P. vivax full-length ectodomain, expressed in
HEK239E cells as previously described [31] (except in the case of repeat immunisations for
Pv12, Pv41 and PvARP, where a Cd4 tag included in the initial constructs was not included),
and purified by nickel affinity chromatography. Immunisations were carried out using
Freunds incomplete (day 0)/Freunds complete adjuvant (days 14, 28, 42, 56 and 70) by Cam-
bridge Research Biochemicals, with a total of 1mg of protein immunised over the course of the
immunisation schedule. The total amount of antigen immunised varied between proteins
(PvGAMA: 0.52mg, PvP12: 0.87mg, PvMSP3.10: 0.69mg, PvMSP7.1: 0.71mg, PvARP: 3.47mg,
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PvCyRPA: 1.35mg, PvDBP: 1.35mg, PvP41: 3.57mg), with the total being equally distributed
across all immunisations. Total IgG was purified using Protein G gravitrap kit (GE healthcare).
Eluted total IgG was concentrated by centrifugation at 4˚C for 30 mins using 100000MWCO
Vivaspin (Sartorius). The concentrate was then dialyzed using a dialysis tube (Millipore) over-
night at 4˚C with 1 litre of RPMI 1640 (Thermo Fisher Scientific), before repeating concentra-
tion if necessary. Total IgG concentration was measured by nanodrop (NanoDrop). For Fab
purification, purified IgG was buffer exchanged in digestion buffer two times in a 5ml 10kDa
concentrator (Amicon Ultra-4, Cat. No. UFC801024), followed by running in a desalting col-
umn. Fab purification was performed according to the manufacturers protocol (Pierce Fab
preparation kit, Cat no.44985), with samples digested for 2 hours at 37 degree with end-to-end
rotation at 20 rpm.
Protein extraction and western blotting
To generate protein extracts, schizont stage parasites enriched from 5–10 mL of culture at
5–10% parasitemia were treated with 0.15% saponin (Sigma Aldrich) and protease inhibitor
(Cat. No. 5892970001, Sigma Aldrich) at 1X for 1min on ice to release parasites from their
host cell. After pelleting and two rounds of washing in ice cold 1X PBS (Sigma Aldrich) with
protease inhibitor 1X, parasites were treated with 1 μl of DNAse I (Thermoscientific) for
30mins at 37˚C., before mixing 1:1 with Laemmli sample buffer 2X and incubating for
30mins-1h at 37˚C to gently denaturate the sample. The pellet was then frozen down at -80˚C
until needed. Samples were diluted 0, 1:5 or 1:10 in Laemmli, and 5μl of the diluted samples
was mixed with 2.5 μl NuPage LDS sample buffer (4X) (Thermo Fisher Scientific), 1 μl NuPage
Reducing agent (10X) (Thermo Fisher Scientific) and deionized water to 6.5 μl. The mixture
was then incubated at 72˚C for 10 mins while shaking at 300 RPM. 10 μl of the sample was
then resolved on a 4–12% bis-trisNuPage gel (Thermo Fisher Scientific) with 1X MOPS SDS
gel buffer (Thermo Fisher Scientific) at 200 V for 50 minutes.
Western blot transfer was carried out in wet conditions at 30V for 60min, and membrane
blocked overnight while shaking at 4˚C in 5% milk (Marvel) containing 0.077% sodium azide
(Sigma Aldrich). Primary antibodies were diluted in 5% milk/PBS/0.1% TWEEN 20 at concen-
trations as follows: anti-PvGAMA 1:2400; Pvp12, PvMSP7.1 and PvMSP3.10 1:400; Pvp41,
PvARP and PvCyRPA 1:800; PvDBP 1:1600. Primary incubation was carried out overnight at
4˚C. Blots were then washed three times, each 10mins, in PBST (1X PBS and 0.1% Tween),
before incubating with secondary anti-Rabbit HRP (Abcam) at 1:20000 dilution in 5% milk/
PBS/0.1% for 45 mins at room temperature. Blots were washed again three times, each 10mins,
in PBST before developing with ECL prime Western Blotting detection reagent, (GE Health-
care). Expected molecular weight of the P. vivax candidate proteins and their orthologous pro-
teins in P. knowlesi was predicted using Protein Molecular Weight calculator (available at
https://www.bioinformatics.org/sms/prot_mw.html) based on the amino acid sequences of the
respective protein sequences from PlasmoDB.
Immunofluorescence assays
Cells were synchronized, harvested from culture and enriched using Histodenz as described
above based on [40]. These were then washed with 1X PBS (Sigma Aldrich) for 5 mins and
fixed with 4% paraformaldehyde (Agar scientific)/ 0.0075% glutaraldehyde (Sigma Aldrich) in
1X PBS for 30 minutes at room temperature, followed up with washing in 1x PBS while shak-
ing for 5 mins. Thin smears of fixed cells were made on Poly-L-Slides (Sigma Aldrich) and
stored in -80˚C freezer until needed. For processing, slides were incubated briefly at room
temperature, permeabilized with 0.1% Triton X-100 (Sigma Aldrich) in 1X PBS for 30 mins at
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room temperature then washed once with 1x PBS while shaking for 5 mins. Blocking was car-
ried out overnight at 4˚C in a humidified dark chamber using Blocking Aid Solution (Thermo
Fisher Scientific). Co-localising antibodies were obtained for P. falciparum PfGAP45 [80]
which we have shown cross-reacts with P. knowlesi, PfAMA1 (obtained through BEI
Resources, NIAID, NIH: Monoclonal Anti-Plasmodium Apical Membrane Antigen 1, Clone
28G2 (producted in vitro), MRA-897A, contributed by Alan W. Thomas) which is reported to
cross-react with all Plasmodium species, and for P. knowlesi PkMSP1 [81]. Primary antibody
diluted in Blocking Aid Solution (Anti-PvGAMA 1:1200; Pvp12, PvMSP7.1 and PvMSP3.10
1:200; PvARP 1:400; PvCyRPA and PvDBP 1:800; Pvp41 1:200, PkMSP1-19 1:2000; PfAMA1
1:1000) was then added and incubated overnight in a humidified dark chamber at 4˚C fol-
lowed by washing three times for 5 mins in 1X PBS while shaking. Secondary antibody diluted
in Blocking Aid Solution (Alexa Fluor 555 Goat-anti rabbit (Thermo Fisher Scientific) (1:500)
for anti-P. vivax rabbit polyclonals and Alexa Fluor 488 Goat-anti rat (Thermo Fisher Scien-
tific) (1:500) for PkMSP1-19 and PfAMA1) was then added and incubated 1 hour in a humidi-
fied dark chamber at room temperature followed by washing three times for 5 mins in 1X PBS
while shaking. Hoechst 33342 (Thermo Fisher Scientific), for nucleus staining, was diluted
1:3000 in 1x PBS (Sigma Aldrich) then added and incubated for 10 mins in a humidified dark
chamber at room temperature with subsequently washing three times for 5 mins in 1X PBS
while shaking. The cells were later mounted with Pro-Long Gold mounting solution (Thermo
Fisher Scientific), covered with cover-glass (VWR), left to cure for 24 hours in dark and dry
chamber at room temperature and eventually sealed with slide sealer (Biotium), before imag-
ing on a Leica DMi8.
Invasion assays
Two millilitres of O+ erythrocytes at 2% hematocrit in incomplete culture media were labelled
using 2 μl of a stock of 1 mM Far-red Cell Trace (Thermo Fisher Scientific); control unstained
erythrocytes were incubated with 2 μl of Dimethyl-sulphoxide (DMSO; Sigma Aldrich). After
2 hours of incubation at 37˚C while shaking, labelled erythrocytes were washed twice using
complete media, then the cells were resuspended in complete media to 2% hematocrit in 2 ml
final volume. For test samples, labelled erythrocytes were mixed with synchronized rings at 4%
parasitemia (generated by Histodenz synchronisation as described above) and serial dilutions
of anti-P. vivax antibodies(with all dilutions made using incomplete medium), while for con-
trols samples, the same components were mixed except no antibodies were used rather only
incomplete media was added Each test sample therefore contained 20 μl infected erythrocytes,
20 μl stained erythrocytes, Xμl of diluted total IgG (Xμl because the antibodies were in varying
stock concentrations therefore requiring different volumes to be added to get the same final
concentrating). Control wells contained 40 μl of erythrocytes only, or 20 μl of infected erythro-
cytes/20 μl of unstained erythrocytes, or 40 μl of stained erythrocytes only, or 20 μl of infected
erythrocytes and 20 μl of stained erythrocytes, to control for gating in the flow cytometry.
Finally all the above treatments were supplemented with 2.2 μl of a mixture of serum, hypo-
xanthine and gentamicin (at a ratio of 2, 0.18 and 0.009 respectively). Triplicates of each com-
bination were incubated in a 96 well plate for 24 hours in a gassed chamber. To quantify
parasite invasion, samples were centrifuged for 3 mins at 450g (acceleration 9, brake 3) at
room temperature, supernatant was removed and samples were labelled with SYBR green I
nucleic acid dye (Thermo Fisher Scientific) for 1 hour at 37˚C while shaking at 52 rpm. After
two washes with 100 μl 1 X PBS (Sigma Aldrich), samples were resuspended in 100 μl of 1 X
PBS (Sigma Aldrich) and parasites quantified using FACS (Cytoflex, Becton and coulter) as
previously described [82]. Data was analyzed using FlowJo then using Excel, invasion was
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calculated as the percentage of erythrocytes that were both SYBR green and Far-red Cell Trace
positive as compared to only DMSO treated erythrocytes. The results were then plotted using
the following Python packages: Seaborn [83], Matplotlib [84], Pandas [85], statannot [86] in
PyCharm Community Edition (JetBrains s.r.o.). IC50 was determined using Robust linear
regression model (RLM) using the Python package statsmodels [87].
Genetic modification
Gene repair construct design and assembly. Constructs, guide RNAs and primers
(S1–S6 Tables) were designed with [88] and [89]. Synthetic DNA codon optimization was
performed using gblocks Gene Fragments (IDT) (PvGAMA_regions1 & 3, PvARP_region1)
and GeneArt Gene Synthesis (Thermo Fischer Scientific) (Pv12, Pv41, PvARP_region3).
PvGAMA_regions2 and PvARP_regions3 were amplified from expression constructs previ-
ously generated by [31]. Other fragments were amplified from P. knowlesi genomic DNA,
purified from saponin-lysed P. knowlesi infected erythrocytes using DNA blood kit (Qiagen)
according to the manufacturer’s protocol. gRNA and gene knockout vectors were assembled
in vectors kindly provided by the Moon lab [46], and allele replacement vectors were assem-
bled in PUC19 using Gibson assembly according to the manufacturer’s protocol (NEB), using
PCR products amplified using KAPA HiFi HotStart ReadyMixPCR Kit (KAPABiosystems)
and purified using gel isolation kits (Macherey and Nagel). Primers (S1 and S2 Tables) and
PCR programs (S3 Table: KAPA2M for all of constructs except KAP121M for final amplifica-
tion of Pkgama replacement insert) are listed in the Supplementary Material.
Assembly of Cas9/gRNA vectors. The cloning vector (pCas9/sg_GOI [46]) was digested
using BtgZI (NEB), purified using a gel purification kit (Macherey and Nagel), and treated
with shrimp alkaline phosphatase (NEB) to dephosphorylate vector ends. Guide RNAs (S5
Table) were reconstituted by mixing 1 μl of 100 μM stocks of the forward and reverse strands
for each guide with 1 μl of 10x ligation buffer (NEB), 0.5 μl T4 polynucleotide kinase (NEB)
and 65 μl nuclease free PCR water. Annealing was carried out by incubating at 37˚C for 30
min, then increasing to 94˚C for 5 min before cooling at 25˚C at a ramp speed of 5˚C per-min.
Annealed primers were then diluted to 1 μl in 200 μl and ligated (NEB) to the digested and
dephosphorylated Cas9 vector. Three gRNAs were constructed for each gene target.
Vectors were transformed into chemically competent E. coli according to the manufactur-
er’s protocol (NEB), and grown overnight. Resulting colonies were screened by colony PCR
using GoTaq Green PCR master mix (Promega), with 1 μl of Pk5’ UTR forward and Pk3’UTR
reverse primers for each respective construct. Positive colonies were expanded and DNA puri-
fied using a miniprep purification kit (Macherey and Nagel) and sequenced to confirm con-
struct integrity (GATC/Eurofins). Sequencing data was analyzed using Benchling and Seqman
Pro (DNA star Navigator); positive constructs were expanded and purified for transfection
using a maxiprep purification kit (Macherey and Nagel).
Transfection
Transfection was performed largely as described in [40]. Late stage P. knowlesi parasites were
enriched using Histodenz as described above. In each transfection cuvette (Lonza), 10 μl of
schizonts was mixed with 100 μl of P3 solution (Lonza) containing 30 μg each of the relevant
donor and three guide vectors. Transfections were carried out using program FP158 (Amaxa
Nucleofector, Lonza), and the contents were then immediately transferred into a 2 ml sterile
eppendorf tube containing 500 μl of complete culture media mixed with 190 μl uninfected
erythrocytes. The transfection mix was incubated at 37˚C while shaking at 800 rpm in a ther-
momixer for 30mins, before being transferred into a 6 well plate, gassed and incubated at 37˚C
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for one parasite life cycle. After this selection was applied with 100 nM pyrimethamine (Santa
Cruz Biotechnology Inc). For three days, the cultures were monitored by smearing and selection
done by changing the media and replacing with fresh media containing 100 nM pyrimethamine
(Santa Cruz Biotechnology Inc). On day 4 post transfection the cultures were diluted 1/3 in 5ml
fresh media containing 100 nM pyrimethamine and 100 μl erythrocytes. The cultures were then
maintained and monitored after every 2nd cycle by smearing/parasitemia counting, with media
changed or cultures split as appropriate. Samples where parasites re-appeared were expanded in
a total volume of 50 ml with erythrocytes at 2% hematocrit until parasitemia was greater than 5%.
DNA was then isolated using a DNA Blood kit (Qiagen) and analysed using gene-specific primers
(S6 Table) and PCR program KAPA18C (S3 Table). Cultures that contained only modified para-
sites were phenotyped without cloning, while those that genotyping showed had both modified
and WT genotyping bands were cloned by limiting dilution and plaque cloning in flat-bottomed
96-well plates. Wells containing single plaques were identified using an EVOS microscope (4x
objective, transmitted light), expanded, and DNA isolated and genotyped as described above as
well as whole genome sequenced. Whole Genome Sequencing analysis was performed on the
Welcome Sanger Institute Cluster using bowtie2 [90] and samtools [91]. Visualisation was per-
formed using Integrative Genomics Viewer [92] as described in [93].
Growth rate assays for genetically modified lines
Genetically modified P. knowlsei strains as well as the wild-type control were synchronised
using Histodenz. On Day 0 these cultures were diluted to 4% parasitemia of tightly synchro-
nised rings then mixed with equal volumes of uninfected erythrocytes. These were then sup-
plemented with 2.2 μl of a mixture of serum, hypoxanthine and gentamicin (at a ratio of 2,
0.18 and 0.009 respectively). Triplicates of each combination were incubated in a 96 well plate
for 24 hours in a gassed chamber. After these 24 hours i.e. Day 1, the number of infected cells
was determined as following; samples were centrifuged for 3 mins at 450g (acceleration 9,
brake 3) at room temperature, supernatant was removed and samples were labelled with SYBR
green I nucleic acid dye (Thermo Fisher Scientific) for 1 hour at 37˚C while shaking at 52 rpm.
After two washes with 100 μl 1 X PBS (Sigma Aldrich), samples were resuspended in 100 μl of
1 X PBS (Sigma Aldrich) and parasites quantified using FACS (Cytoflex, Becton and coulter)
as previously described [82]. Parasitemia was then quantified as the number of cells that were
SYBR green positive as a percentage of the number of cells measured. After quantification, cul-
tures were split and diluted to equal parasitemia. This process was repeated over a total of 19
cycles. Data was analyzed using FlowJo (FlowJo) and Excel (Microsoft Office). Growth rate
was quantified by dividing the parasitemia obtained before splitting in the current cycle with
parasitemia obtained after splitting on the previous cycle, and average growth rate calculated
over the entire 19-cycle experiment. The results were then plotted using the following R pack-
ages; ggplot2 [94], ggpubr [95], cowplot [96], magrittr [97], readxl [98] and dplyr [99] in
R-Studio (R-Studio Inc).
Supporting information
S1 Fig. Preimmune antibody controls for immunolocalization. Localisation of using pre-
immune serum from rabbits before they were immunized with PvGAMA, PvDBP, PvARP,
PvCyRPA, PvMSP7.1 and Pv41, respectively. No specific staining is detected using Alexa
555-labeled anti-rabbit secondary antibody. Merge is an overlay of Alexa 555 and Hoeschst
(parasite nuclei). Scale bar is 2 micrometers.
(TIFF)
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S2 Fig. Colocalization of P. knowlesi proteins using polyclonal anti-P. vivax antibodies to
P. vivax vaccine candidates with antibodies to PkMSP1 and PfGAP45. P. knowlesi proteins
were localised in schizont and trophozoite (troph) stage parasites using rabbit polyclonal anti-
bodies raised against Pv12, PvMSP7.1 and Pv41 and co-stained with rat antibodies against A)
anti-PkMSP1 or B) anti-PfGAP45 for colocalization (origin of antibodies is described in Meth-
ods). Alexa Fluor 555 goat-anti rabbit and Alexa Fluor 488 goat-anti rat were used as second-
ary antibodies, and parasite DNA localised using Hoechst 33342. The first Merge column is
one is an overlay of Alexa 555 and Alexa488 staining, while the second Merge column is an
overlay of Alexa 555, Alexa488 and Hoeschst. Scale bar is 2 micrometers.
(TIFF)
S3 Fig. Colocalization of P. knowlesi proteins using polyclonal anti-P. vivax antibodies to
P. vivax vaccine candidates with antibodies to proteins PkMSP1 and PfAMA1. P. knowlesi
proteins were localised in schizont stage parasites using rabbit polyclonal antibodies raised
against P. vivax vaccine candidates and co-stained with rat antibodies against A) anti-PkMSP1
or B) anti-PfAMA1 for colocalization (origin of antibodies is described in Methods). Alexa
Fluor 555 goat-anti rabbit and Alexa Fluor 488 goat-anti rat (MSP1) or mouse (AMA1) were
used as secondary antibodies, and parasite DNA localised using Hoechst 33342. The first
Merge column is one is an overlay of Alexa 555 and Alexa488 staining, while the second
Merge column is an overlay of Alexa 555, Alexa488 and Hoeschst. Scale bar is 2 micrometers.
(TIFF)
S4 Fig. Diagram outlining invasion inhibition assays. A) Synchronized P. knowlesi cultures
at ring stage (IRBC) were mixed with Far-Red Cell Trace dye stained Uninfected RBCs
(SUIRBC) and two-fold serial dilutions from 10 mg/ml to 0.625 mg/ml of purified total IgG.
B) The mixture was incubated for 24 hours under normal culture conditions described in the
Material and Methods section to allow a full cycle of development and invasion to occur. C)
Parasite DNA was labelled with SYBR Green, and newly invaded parasites identified using
two-colour flow cytometry, where new invasions into Far-Red Cell Trace labelled RBCs can be
detected in the upper right quadrant (3—circled).
(TIFF)
S5 Fig. Gene editing strategy to knock out candidate genes. A) General strategy used to
attempt to knock out Pk12, Pkarp, Pkdbpalpha, Pk41 and Pkgama. Plasmids used are Cas9/
gRNA vector and donor vector containing eGFP (GFP) flanked with 5’ and 3’ untranslated
region (UTR) for each respective P. knowlesi gene (PkCDS). Primer pairs used for genotyping
are P1&P2 and P3&P4, to test for the presence of wildtype gene, and P1&P5 and P6&P4 to test
for integration of the knockout construct. B) Genotyping of Pk41KO and PkGAMAKO with
above primer pairs as compared to WT. On the right side are the obtained molecular weight in
kilobase pairs (kb).
(TIFF)
S6 Fig. Whole genome sequencing of Pk41 knockout strain. Reads generated from Illumina
sequencing of Pk41 knockout strains and the WT strain from which they were generated were
aligned to the P. knowlesi reference genome. Absence of reads in the centre of the gene con-
firms deletion of this locus from the P. knowlesi genome.
(TIFF)
S7 Fig. Whole genome sequencing of PkGAMA knockout strain. Reads generated from Illu-
mina sequencing of PkGAMA knockout strains and the WT strain from which they were gen-
erated were aligned to the P. knowlesi reference genome. Absence of reads in the centre of the
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gene confirms deletion of this locus from the P. knowlesi genome.
(TIFF)
S8 Fig. Comparative Growth rate assay between wildtype P. knowlesi and genetically edited
P. knowlesi strains. WT (P. knowlesi WT, PkMC), Gamako (PkGama knock-out clone),
Gamarep (PkGama replacement clone), p41ko (Pkp41 knock out clone), p41rep (Pkp41
replacement clone), P12rep (Pkp12 replacement clone), and ARPrep (PkARP replacement
clone) strains were tightly synchronised, and parasitemia measured every day using flow
cytometry, then readjusted to the same parasitemia again. Parasitmia was quantified in this
manner for 19 days (ie. over 19 growth cycles) and the average growth rate per cycle calculated
for each strain. All strains were grown in triplicate.
(TIFF)
S9 Fig. Gene editing strategy to replace P. knowlesi target genes with orthologous P. vivax
candidate genes. A) General strategy used to replace pk12, pkarp, pk41 and pkgama with pv12,
pvarp, pv41 and pvgama, respectively. Plasmids used are Cas9/gRNA vector and donor vector
containing the P. vivax coding sequence (PvCDS) flanked with 5’ and 3’ untranslated region
(UTR) for each respective P. knowlesi gene (PkCDS). Primer pairs used for genotyping are
P1&P2 and P3&P4, to test for the presence of the wildtype gene. P1&P5 and P6&P4 to test for
integration of the replacement construct. B) Genotyping of pk12, pkarp, pk41 and pkgama
allele replacement (Rep) using the above primer pairs as compared to WT. On the right side
are the obtained molecular weight in kilobase pairs (kb).
(TIFF)
S10 Fig. Whole genome sequencing of Pk41-Pv41 replacement strain. Reads generated
from Illumina sequencing of PkPv41 allele replacement strains and the WT strain from which
they were generated were aligned to the P. knowlesi reference genome. The P. vivax gene con-
struct was codon optimised to human codons to reduce the chance that recombination would
occur within the ORF, rather than within the flanking regions, and hence favour complete
replacement of the P. knowlesi gene. As a result, reads from the replacement gene do not map
to the P. knowlesi genome, confirming that the endogenous gene has been replaced.
(TIFF)
S11 Fig. Whole genome sequencing of PkGAMA-PvGAMA replacement strain. Reads gen-
erated from Illumina sequencing of PkPvGAMA allele replacement strains and the WT strain
from which they were generated were aligned to the P. knowlesi reference genome. The P.
vivax gene construct was codon optimised to human codons to reduce the chance that recom-
bination would occur within the ORF, rather than within the flanking regions, and hence
favour complete replacement of the P. knowlesi gene. As a result, reads from the replacement
gene do not map to the P. knowlesi genome, confirming that the endogenous gene has been
replaced.
(TIFF)
S12 Fig. Whole genome sequencing of PkARP-PvARP replacement strain. Reads generated
from Illumina sequencing of PkPvARP allele replacement strains and the WT strain from
which they were generated were aligned to the P. knowlesi reference genome. The P. vivax
gene construct was codon optimised to human codons to reduce the chance that recombina-
tion would occur within the ORF, rather than within the flanking regions, and hence favour
complete replacement of the P. knowlesi gene. As a result, reads from the replacement gene do
not map to the P. knowlesi genome, confirming that the endogenous gene has been replaced.
(TIFF)
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S13 Fig. Whole genome sequencing of Pk12-Pv12 replacement strain. Reads generated
from Illumina sequencing of PkPv12 allele replacement strains and the WT strain from which
they were generated were aligned to the P. knowlesi reference genome. The P. vivax gene con-
struct was codon optimised to human codons to reduce the chance that recombination would
occur within the ORF, rather than within the flanking regions, and hence favour complete
replacement of the P. knowlesi gene. As a result, reads from the replacement gene do not map
to the P. knowlesi genome, confirming that the endogenous gene has been replaced.
(TIFF)
S14 Fig. Comparison of IC50 resulting from invasion inhibitory assays of P. knowlesi wild-
type and allele replacement mutants using antibodies against P. vivax proteins. Using the
invasion inhibition assay data from Fig 8 above, IC50 in mg/ml was generated using Robust
linear regression model. To determine if there were statically significant differences between
these values, IC50 values obtained from the allele replacement mutants (Replacements) were
independently compared to P. knowlesi wild-type IC50 (PKWT) that had been treated with the
same antibodies using Mann-Whitney-Wilcoxon test with a p value threshold of 5.00e-02. �:
1.00e-02< p value < = 5.00e-02. ��: 1.00e-03 < p value< = 1.00e-02.
(TIFF)
S15 Fig. Growth inhibition by total IgG and Fab fragments from a second batch of rabbit
polyclonal antibodies. Rabbit polyclonal antibodies were raised against PvDBP, Pv12,
Pv41 and PvGAMA as described in the Methods, and used in Growth Inhibition Assays as out-
lined in S4 Fig using either a single dose of purified Fab (A) or a dose dilution series of total
IgG (B).
(TIFF)
S1 Table. Primers used for amplification of sequences used for gene knockout construct
generation. Contains a list of all primers used for generation of Plasmodium knowlesi gene
knockout constructs.
(XLSX)
S2 Table. Primers use for amplification of sequences used for gene replacement construct
generation, Contains a list of all primers used for generation of Plasmodium knowlesi gene
replacement constructs.
(XLSX)
S3 Table. List of PCR programmes used for construct generation. Details of PCR cycle tem-
peratures and times for generation of Plasmodium knowlesi knockout and gene replacement
constructs.
(XLSX)
S4 Table. Genetic modification construct sequences. Vector sequences for Plasmodium
knowlesi knockout and gene replacement constructs.
(XLSX)
S5 Table. Guide RNA sequences. Guide RNA sequences used for CRISPR-Cas9 targeted
homolous replacement approach.
(XLSX)
S6 Table. List of genotyping and sequencing primers used for construct verification. Contains
a list of all primers used for genotyping of genetically modified Plasmodium knowlesi lines.
(XLSX)
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